Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN 株式レポート

時価総額:US$116.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Regeneron Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /56

Regeneron Pharmaceuticalsの総株主資本は$27.0B 、総負債は$2.0Bで、負債比率は7.3%となります。総資産と総負債はそれぞれ$34.4Bと$7.4Bです。 Regeneron Pharmaceuticalsの EBIT は$4.0Bで、利息カバレッジ比率-8.1です。現金および短期投資は$10.5Bです。

主要情報

7.0%

負債資本比率

US$1.98b

負債

インタレスト・カバレッジ・レシオ-7.3x
現金US$9.81b
エクイティUS$28.21b
負債合計US$7.88b
総資産US$36.09b

財務の健全性に関する最新情報

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

財務状況分析

短期負債: REGNの 短期資産 ( $18.9B ) が 短期負債 ( $3.6B ) を超えています。

長期負債: REGNの短期資産 ( $18.9B ) が 長期負債 ( $3.8B ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: REGN総負債よりも多くの現金を保有しています。

負債の削減: REGNの負債対資本比率は、過去 5 年間で0%から7.3%に増加しました。

債務返済能力: REGNの負債は 営業キャッシュフロー によって 十分にカバー されています ( 238.9% )。

インタレストカバレッジ: REGN支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。


貸借対照表


健全な企業の発掘